Table 3.
Trends in first-line treatment in patients with depression in Flanders, Belgium (2000-2019)
| SUMMARY | Trend 1 | Trend 2 | Trend 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Medication (%) | Year 2000 | Year 2019 | AAPC (95% CI) | Years | APC (95% CI) | Years | APC (95% CI) | Years | APC (95% CI) |
| Total | 26.42 | 40.16 | 2.4 (1.0;3.7) | 2000-2002 | 7.1 (-5.4;21.3) | 2002-2016 | 0.2 (-0.3;0.7) | 2016-2019 | 9.6 (5.7;13.6) |
| Women | 26.75 | 41.92 | 2.4(1.3;3.6) | 2000-2002 | 8.3 (-2.6;20.5) | 2002-2016 | 0.4 (-0.1;0.8) | 2016-2019 | 8.6 (5.2;12) |
| Men | 25.58 | 36.51 | 1.8 (0.9;2.7) | 2000-2016 | 0.1 (-0.5;0.6) | 2016-2019 | 11.6 (6.0;17.5) | ||
| ANTIDEPRESSANTS | |||||||||
| SSRI | 15.89 | 22.28 | 1.8 (0.4;3.1) | 2000-2004 | 5.0 (-0.5;10.8) | 2004-2014 | -2.4 (-3.6;-1.2) | 2014-2019 | 8.0 (5.3;10.7) |
| SNRI | 2.87 | 9.95 | 6.1 (4.6;7.6) | 2000-2010 | 9.1 (7.4;10.8) | 2010-2016 | -0.4 (-3.4;2.7) | 2016-2019 | 9.7 (3.8; 16.1) |
| TCA | 6.09 | 5.07 | -0.7 (-1.2;-0.1) | 2000-2010 | -2.0 (-2.8;-1.1) | 2010-2019 | 0.7 (0.0;1.5) | ||
| Neuromodulators | 5.62 | 11.65 | 3.9 (2.2;5.5) | 2000-2002 | 11.9 (-3.7;30.2) | 2002-2016 | 1.5 (1.0;2.1) | 2016-2019 | 10.0 (5.8;14.3) |
| MAOI | 0.29 | 0.06 | -6.1 (-10.1;-1.9) | 2000-2005 | -22.8 (-33.6;-10.1) | 2005-2019 | 0,7 (-2.8;4.3) | ||
| Bupropion | 0.36 | 2.19 | 7.4(5.4;9.5) | 2000-2019 | 7.4(5.4;9.5) | ||||
| OTHER | |||||||||
| Antipsychotics | 7.28 | 8.29 | 0.3 (-0.2;0.8) | 2000-2019 | 0.3 (-0.2;0.8) | ||||
| Anxiolytics | 19.52 | 18.09 | -0.7 (-1.1;-0.2) | 2000-2013 | -1.2(-1.7;-0.8) | 2013-2019 | 0.5 (-0.7;-1.6) | ||
| Hypnotics and sedatives | 11.27 | 14.77 | 1.3 (0.8;1.7) | 2000-2009 | 2.0 (1.5;2.5) | 2009-2017 | -0.1 (-0.7;0.5) | 2017-2019 | 3.5 (0.3;6.8) |